Since our initial financing in 2004, Accelerons goal has been to develop innovative therapies. Our company has built in-house drug development capabilities, allowing us to focus our creativity and innovation on the biology of the Growth and Differentiation Factor (GDF) protein family, while streamlining the development of novel therapies.

This strategy has already yielded a rich pipeline of compounds that have the potential to be therapeutic breakthroughs for a number of devastating diseases. Our approach has opened a completely new area of GDF-targeted therapies that can modulate the growth and repair of a variety of tissue systems, offering new hope and benefits to patients.

Focus on the GDF Family of Proteins

Acceleron is establishing itself as the premier company in GDF-targeted therapies. We have developed an unparalleled expertise in GDF biology, and our scientific advisory board consists of leaders and pioneers in the field. Our discoveries and technology have allowed us to unleash the therapeutic promise of this protein family, building a powerful and productive discovery platform.

Designed and Built for Speed

In anticipation of a robust pipeline and to speed our compounds into the clinic, Acceleron chose to invest early in a broad drug development infrastructure. By bringing potentially rate-limiting functions in-house, Acceleron has been able to control the quality, innovation and speed of R&D. Acceleron capabilities range from discovery biology, protein engineering, cell line development, pre-clinical pharmacology, clinical development to pilot and GMP manufacturing.